December 6, 2018 / 10:34 PM / 6 months ago

Roche's lung cancer combo treatment wins FDA approval

Dec 6 (Reuters) - Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with chemotherapy was approved by the U.S. Food and Drug Administration as a first-line treatment for a form of lung cancer.

The Tecentriq regimen showed significant survival benefit in the initial treatment of metastatic non-squamous non-small cell lung cancer, the drugmaker said.

The agency’s approval comes a day after the drug won priority review from the U.S. regulator. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Anil D’Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below